Efficacy and Safety of Sirolimus-Eluting Stent With Biodegradable Polymer Ultimaster™ in Unselected Korean Population: A Multicenter, Prospective, Observational Study From Korean Multicenter Ultimaster Registry
- Author:
Soohyung PARK
1
;
Seung-Woon RHA
;
Byoung Geol CHOI
;
Jae-Bin SEO
;
Ik Jun CHOI
;
Sung-Il WOO
;
Soo-Han KIM
;
Tae Hoon AHN
;
Jae Sang KIM
;
Ae-Young HER
;
Ji-Hun AHN
;
Han Cheol LEE
;
Jaewoong CHOI
;
Jin Soo BYON
;
Markz RMP SINURAT
;
Se Yeon CHOI
;
Jinah CHA
;
Su Jin HYUN
;
Cheol Ung CHOI
;
Chang Gyu PARK
Author Information
- Publication Type:Original Research
- From:Korean Circulation Journal 2024;54(6):339-350
- CountryRepublic of Korea
- Language:EN
-
Abstract:
Background and Objectives:Ultimaster™, a third-generation sirolimus-eluting stent using biodegradable polymer, has been introduced to overcome long term adverse vascular events, such as restenosis or stent thrombosis. In the present study, we aimed to evaluate the 12-month clinical outcomes of Ultimaster™ stents in Korean patients with coronary artery disease.
Methods:This study is a multicenter, prospective, observational registry across 12 hospitals. To reflect real-world clinical evidence, non-selective subtypes of patients and lesions were included in this study. The study end point was target lesion failure (TLF) (the composite of cardiac death, target vessel myocardial infarction [MI], and target lesion revascularization [TLR]) at 12-month clinical follow up.
Results:A total of 576 patients were enrolled between November 2016 and May 2021. Most of the patients were male (76.5%), with a mean age of 66.0±11.2 years. Among the included patients, 40.1% had diabetes mellitus (DM) and 67.9% had acute coronary syndrome (ACS).At 12 months, the incidence of TLF was 4.1%. The incidence of cardiac death was 1.5%, MI was 1.0%, TLR was 2.7%, and stent thrombosis was 0.6%. In subgroup analysis based on the presence of ACS, DM, hypertension, dyslipidemia, or bifurcation, there were no major differences in the incidence of the primary endpoint.
Conclusions:The present registry shows that Ultimaster™ stent is safe and effective for routine real-world clinical practice in non-selective Korean patients, having a low rate of adverse events at least up to 12 months.
